This study is focused on the long-term safety and effectiveness of a medicine called pembrolizumab, for people with advanced tumors. Pembrolizumab, also known as MK-3475, is a treatment that helps the immune system fight cancer. The study has three parts: the First Course Phase, the Survival Follow-up Phase, and the Second Course Phase. Participants may need to receive pembrolizumab or a related combination treatment every 3 or 6 weeks. Some might get up to 35 doses over two years. The study is for those who were already involved in earlier pembrolizumab studies. They must be healthy enough to participate, not pregnant, and agree to use birth control if needed.
- Length: Participation might last up to two years, depending on the treatment phase.
- Visits: Regular visits every 3 or 6 weeks for treatment are required.
- Risks: Possible side effects include hypersensitivity and other health issues; careful monitoring will be provided.
How understandable was the trial content above?
Hard to understand
Easy to understand